# Rocket Pharmaceuticals, Inc. Common Stock (RCKT)

> Rocket Pharmaceuticals, Inc. Common Stock (RCKT) trades at $2.11 (+0.00%) as of 7:39:53 PM EST on Nov 18, 2026, -9.83% over the past month. Market cap is $235.6M, with 9.1 days to cover in short interest.

Canonical: https://massive.com/quote/rckt
Data as of: 2026-11-19T00:39:53.754Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$2.11** +0.00 (+0.00%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$2.07** -0.04 (-1.90%)
As of 7:39:53 PM EST on Nov 18, 2026 · After hours

## Stock performance

How Rocket Pharmaceuticals, Inc. Common Stock (RCKT) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.00% |
| 1W | -14.92% |
| 1M | -9.83% |
| YTD | -39.89% |
| 1Y | -26.74% |
| 52-wk range | $2.03 – $5.45 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for RCKT: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $2.06 – $2.22 |
| Open | $2.09 |
| Prev close | $2.11 |
| Volume | 2.49M |
| Market cap | $235.6M |
| Shares out | 109.77M |

## Valuation and profitability ratios

Valuation and profitability ratios for Rocket Pharmaceuticals, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 0.72 |
| P/FCF | — |
| ROE | -4.9% |
| ROA | -3.9% |
| Debt/Equity | 0.16 |
| Div yield | 0.00% |

As of Nov 17, 2026

## Insider trading

[Rocket Pharmaceuticals, Inc. Common Stock (RCKT) insider trading](https://massive.com/quote/rckt/insider-trading.md): open-market Form 4 buys and sells by Rocket Pharmaceuticals, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Rocket Pharmaceuticals, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Oct 6, 2026 · Investor presentation
  “Additionally, the Company prepared an investor presentation providing certain updates on the Company's Danon Disease Program used in a corporate webinar on October 6, 2026.”
- Sep 15, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “On September 15, 2026, Rocket Pharmaceuticals, Inc. issued a press release announcing alignment with the U.S. Food and Drug Administration on continued enrollment and dosing and key elements of the global pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease.”
- Aug 27, 2026 · Executive compensation change
  “Pursuant to the Stevens Amendment, if Mr. Stevens' employment is terminated by the Company without Cause or by Mr. Stevens for Good Reason, he is entitled to receive, subject to his execution and non-revocation of a release of claims: (i) a lump sum payment equal to 12 months of his base salary; (ii) any incentive bonus to which he is otherwise entitled for the prior fiscal year; and (iii) a lump sum amount equal to 12 months of COBRA premiums.”
- Aug 3, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On August 3, 2026, Rocket Pharmaceuticals, Inc. (the "Company") issued a press release announcing a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global, pivotal Phase 2 trial of RP-A501 in Danon disease.”
- Jun 30, 2026 · [Executive officer departure](https://massive.com/quote/sec-filings/8-k/executive-departures.md)
  “On June 24, 2026, John Militello informed Rocket Pharmaceuticals, Inc. (the "Company" or "Rocket") of his resignation as VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, effective July 7, 2026, to pursue other opportunities.”

## RCKT short interest

How heavily RCKT is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 9.1 |
| Short interest | 16.24M |
| Avg volume | 1.79M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## RCKT news

The latest news and headlines about Rocket Pharmaceuticals, Inc. Common Stock (RCKT).

- [ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm](https://www.globenewswire.com/news-release/2025/10/23/3172567/0/en/ROCKET-ALERT-Bragar-Eagel-Squire-P-C-is-Investigating-Rocket-Pharmaceuticals-Inc-on-Behalf-of-Long-Term-Stockholders-and-Encourages-Investors-to-Contact-the-Firm.html) · GlobeNewswire Inc. · Oct 23, 2025 · negative sentiment
- [DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions](https://www.globenewswire.com/news-release/2025/08/11/3131112/3448/en/DEADLINE-ALERT-for-RCKT-DDD-TEM-RDDT-Law-Offices-of-Howard-G-Smith-Reminds-Investors-of-Opportunity-to-Lead-Securities-Fraud-Class-Actions.html) · GlobeNewswire Inc. · Aug 11, 2025 · negative sentiment
- [RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT](https://www.globenewswire.com/news-release/2025/08/10/3130551/673/en/RCKT-DEADLINE-TOMORROW-ROSEN-SKILLED-INVESTOR-COUNSEL-Encourages-Rocket-Pharmaceuticals-Inc-Investors-with-Losses-in-Excess-of-100K-to-Secure-Counsel-Before-Important-August-11-Dea.html) · GlobeNewswire Inc. · Aug 10, 2025 · negative sentiment
- [Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit](https://www.benzinga.com/pressreleases/25/08/b47006714/deadline-soon-rocket-pharmaceuticals-inc-rckt-investors-who-lost-money-urged-to-contact-the-law-of) · Benzinga · Aug 8, 2025 · negative sentiment
- [MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit](https://www.globenewswire.com/news-release/2025/08/07/3129886/0/en/MONDAY-INVESTOR-DEADLINE-Robbins-Geller-Rudman-Dowd-Announces-that-Rocket-Pharmaceuticals-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html) · GlobeNewswire Inc. · Aug 7, 2025 · negative sentiment

## About Rocket Pharmaceuticals, Inc. Common Stock

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 202 |
| Listed | Feb 18, 2015 |

[Company website](https://www.rocketpharma.com)

## FAQ

### What is the Rocket Pharmaceuticals, Inc. Common Stock (RCKT) stock price today?

Rocket Pharmaceuticals, Inc. Common Stock (RCKT) is trading at $2.11 (+0.00% on the day) as of 7:39:53 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Rocket Pharmaceuticals, Inc. Common Stock?

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for…

### What is the short interest in RCKT?

As of Oct 30, 2026, RCKT has 16.24M shares short and 9.1 days to cover.

### What exchange is RCKT listed on?

Rocket Pharmaceuticals, Inc. Common Stock (RCKT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time RCKT quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=RCKT`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Rocket Pharmaceuticals, Inc. Common Stock (RCKT) insider trading](https://massive.com/quote/rckt/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
